Bautista-Molano W, Fernández-Ávila DG, Brance ML, Ávila Pedretti MG, Burgos-Vargas R, Corbacho I, Cosentino VL, Díaz Coto JF, Giraldo Ho E, Gomes Resende G, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023;19(11):724–37.

Article  PubMed  Google Scholar 

Tian A, Ma J, Feng K, Liu Z, Chen L, Jia H, Ma X. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res. 2019;14(1):68.

Article  PubMed  PubMed Central  Google Scholar 

Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Min Metab. 2020;38(3):310–15.

Article  CAS  Google Scholar 

Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, De Socio A, Scriffignano S, Alessandri C, Lubrano E. Serum Sclerostin as a possible biomarker in Ankylosing spondylitis: a case-control study. J Immunol Res. 2018;2018:9101964.

Article  PubMed  PubMed Central  Google Scholar 

Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ, Stolina M, Schett G, Bozec A. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013;72(10):1732–6.

Article  CAS  PubMed  Google Scholar 

Soós B, Szentpétery Á, Raterman HG, Lems WF, Bhattoa HP, Szekanecz Z. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2022;18(5):249–57.

Article  PubMed  Google Scholar 

Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis. 2016;75(8):1486–93.

Article  PubMed  Google Scholar 

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.

Article  PubMed  Google Scholar 

Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24.

Article  CAS  PubMed  Google Scholar 

Althoff CE, Feist E, Burova E, Eshed I, Bollow M, Hamm B, Hermann KG. Magnetic resonance imaging of active sacroiliitis: do we really need gadolinium? Eur J Radiol. 2009;71(2):232–6.

Article  PubMed  Google Scholar 

Althoff CE, Sieper J, Song IH, Haibel H, Weiß A, Diekhoff T, Rudwaleit M, Freundlich B, Hamm B, Hermann KG. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis. 2013;72(6):967–73.

Article  PubMed  Google Scholar 

Krohn M, Braum LS, Sieper J, Song IH, Weiss A, Callhoff J, Althoff CE, Hamm B, Hermann KG. Erosions and fatty lesions of sacroiliac joints in patients with axial spondyloarthritis: evaluation of different MRI techniques and two scoring methods. J Rheumatol. 2014;41(3):473–80.

Article  PubMed  Google Scholar 

Min HK, Lee J, Ju JH, Park SH, Kwok SK. Alcohol consumption as a predictor of the progression of spinal structural damage in axial spondyloarthritis: data from the catholic Axial Spondyloarthritis COhort (CASCO). Arthritis Res Ther. 2019;21(1):187.

Article  PubMed  PubMed Central  Google Scholar 

Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388–98.

Article  PubMed  Google Scholar 

Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, Landewé R. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52–9.

Article  PubMed  Google Scholar 

Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, Mansmann U, Rudwaleit M, Poddubnyy D. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford). 2019;58(9):1556–64.

Article  CAS  PubMed  Google Scholar 

Rademacher J, Siderius M, Gellert L, Wink FR, Verba M, Maas F, Tietz LM, Poddubnyy D, Spoorenberg A, Arends S. Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. Semin Arthritis Rheum. 2022;53:151974.

Article  CAS  PubMed  Google Scholar 

Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H, Veeger NJ, Brouwer E, van der Veer E. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS ONE. 2014;9(6):e99685.

Article  PubMed  PubMed Central  Google Scholar 

Serdaroğlu Beyazal M, Erdoğan T, Türkyılmaz AK, Devrimsel G, Cüre MC, Beyazal M, Sahin I. Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis. Clin Rheumatol. 2016;35(9):2235–41.

Article  PubMed  Google Scholar 

Yang J, Xu S, Chen M, Yuan Y, Zhang X, Ma Y, Wu M, Han R, Hu X, Liu R, et al. Serum sclerostin and bone morphogenetic Protein-2 levels in patients with Ankylosing spondylitis: a Meta-analysis. Calcif Tissue Int. 2019;105(1):37–50.

Article  CAS  PubMed  Google Scholar 

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60(11):3257–62.

Article  PubMed  Google Scholar 

Gómez-García I, Ladehesa-Pineda ML, Diaz-Tocados JM, López-Medina C, Abalos-Aguilera MC, Ruiz-Vilches D, Paz-Lopez G, Gonzalez-Jimenez A, Ranea JAG, Escudero-Contreras A, et al. Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation. Front Endocrinol (Lausanne). 2024;15:1227196.

Article  PubMed  Google Scholar 

Iaremenko O, Shynkaruk I, Fedkov D, Iaremenko K, Petelytska L. Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis. Rheumatol Int. 2020;40(12):2057–63.

Article  CAS  PubMed  Google Scholar 

Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther. 2012;14(5):R216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gercik O, Solmaz D, Coban E, Iptec BO, Avcioglu G, Bayindir O, Kabadayi G, Topal FE, Kozaci D, Akar S. Evaluation of serum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin, inflammation, and spinal damage. Rheumatol Int. 2019;39(5):835–40.

Article  CAS  PubMed  Google Scholar 

Descamps E, Molto A, Borderie D, Lories R, Richard CM, Pons M, Roux C, Briot K. Changes in bone formation regulator biomarkers in early axial spondyloarthritis. Rheumatology (Oxford). 2021;60(3):1185–94.

Article  CAS  PubMed  Google Scholar 

Sun W, Tian L, Jiang L, Zhang S, Zhou M, Zhu J, Xue J. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis. Clin Rheumatol. 2019;38(4):989–95.

Article  PubMed  Google Scholar 

Guo Y, Jiang D, Mai Z, Chen Y, Li T, Gao G. Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. Clin Rheumatol. 2023;42(6):1585–92.

Article  PubMed  Google Scholar